Biogen (BIIB) is back in focus after the FDA granted Breakthrough Therapy Designation to its spinal muscular atrophy candidate salanersen, while fresh Phase 3 data for lupus drug dapirolizumab pegol highlighted progress across its pipeline.

These pipeline updates come after a stronger period for the stock, with an 8.96% 90 day share price return and a 56.95% 1 year total shareholder return, in contrast with weaker three and five year total shareholder returns.

If Biogen's neurology focus has your attention, it can be useful to see what else is gaining traction in healthcare, starting with 39 healthcare AI stocks

With Biogen trading at US$198.64 and internal models suggesting a sizeable intrinsic discount, along with a modest gap to analyst targets, investors may ask whether there is still a buying opportunity here or if future growth is already priced in.

Most Popular Narrative: 9.4% Undervalued

Biogen's most followed narrative puts fair value at about $219, compared with the last close at $198.64. This frames the stock as trading at a discount and puts the focus firmly on what is driving that gap.

Biogen is positioned for long-term growth through expanding global access to key therapies, leveraging increasing disease diagnoses and improved healthcare infrastructure. Streamlined operations, diverse late-stage pipeline, and digital engagement efforts are expected to strengthen earnings and reduce future revenue volatility.

Curious what sits behind that valuation gap and earnings power story? The narrative leans on steady top line expansion, wider margins, and a richer future earnings multiple. The mix of slower headline growth, higher profitability, and a premium P/E creates a very specific earnings and cash flow path. The full breakdown shows exactly how those pieces are meant to add up.

Result: Fair Value of $219.27 (UNDERVALUED)

However, this depends on a few key swing factors, including pressure on the ex U.S. MS portfolio from generics and whether new launches like LEQEMBI and ZURZUVAE scale as hoped.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

Mixed messages in the narrative so far? Take a closer look at the data, pressure test the assumptions, and weigh 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Biogen is on your radar, do not stop there, broaden your watchlist now so you are not relying on a single stock story.

• Spot potential turnaround stories early by scanning 23 elite penny stocks with strong financials that already back up their price with solid financials.
• Zero in on opportunities trading below internal estimates of worth by reviewing the 47 high quality undervalued stocks before the crowd catches on.
• Prioritize resilience and capital preservation by focusing on 68 resilient stocks with low risk scores that score well on stability while still allowing for potential returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.